Cargando…
Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
T cells play a critical role in antitumor immunity, where T cell activation is regulated by both inhibitory and costimulatory receptor signaling that fine-tune T cell activity during different stages of T cell immune responses. Currently, cancer immunotherapy by targeting inhibitory receptors such a...
Autores principales: | Liu, Guizhong, Luo, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272836/ https://www.ncbi.nlm.nih.gov/pubmed/37334375 http://dx.doi.org/10.3389/fimmu.2023.1208788 |
Ejemplares similares
-
Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012) -
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
por: Zapata, Juan M., et al.
Publicado: (2018) -
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020) -
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
por: Claus, Christina, et al.
Publicado: (2023) -
4-1BB (CD137) in anticancer chimeras
por: Melero, Ignacio, et al.
Publicado: (2020)